1. Kemper, A. R., Duke University Evidence-based Practice Center,, United States., & Effective Health Care Program (U.S.). (2018). Attention deficit hyperactivity disorder: Diagnosis and treatment in children and adolescents.
2. FDA-Approved Drugs to Treat ADHD. (March 01, 2018). Journal of Psychosocial Nursing and Mental Health Services, 56, 3, 13-14.
3. In Procyshyn, R. M. (2017). Clinical handbook of psychotropic drugs. Boston, MA: Hogrefe.
4. Brady, G. (May 01, 2014). Children and ADHD: seeking control within the constraints of diagnosis. Children & Society, 28, 3, 218-230.
5. Minder, F., Zuberer, A., Brandeis, D., & Drechsler, R. (August 01, 2018). A Review of the Clinical Utility of Systematic Behavioral Observations in Attention Deficit Hyperactivity Disorder (ADHD). Child Psychiatry & Human Development, 49, 4, 572-606.
6. Clavenna, A., & Bonati, M. (January 01, 2016). Safety and Tolerability of Medications for ADHD.
7. Li, A., Yeo, K., Welty, D., & Rong, H. (April 02, 2018). Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. Pediatric Drugs, 20, 2, 181-194.
The download will start shortly.